Corcept Therapeutics Inc (CORT) stock
CORTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 11/30349% above fair value
$72.94−0.77 (-1.04%)
Close on Nov 13, 2026Market cap $7.88BP/E 173.7Yield –
Corcept Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Corcept Therapeutics's ebitda for the twelve months ending Jun 30, 2026 was $8.08M, down 92.2% year over year. For fiscal 2025 it was $45.95M, down 66.6% from the year before. The highest annual figure on record is $137.75M in fiscal 2024.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $45.95M | -66.6% |
| FY2024 | Dec 31, 2024 | $137.75M | +27.2% |
| FY2023 | Dec 31, 2023 | $108.32M | -4.9% |
| FY2022 | Dec 31, 2022 | $113.89M | -9.3% |
| FY2021 | Dec 31, 2021 | $125.55M | -2.5% |
| FY2020 | Dec 31, 2020 | $128.73M | +14.6% |
| FY2019 | Dec 31, 2019 | $112.31M | +25.2% |
| FY2018 | Dec 31, 2018 | $89.73M | +69.4% |
| FY2017 | Dec 31, 2017 | $52.96M | +415.9% |
| FY2016 | Dec 31, 2016 | $10.27M | – |
| FY2015 | Dec 31, 2015 | -$3.29M | – |
| FY2014 | Dec 31, 2014 | -$27.48M | – |
| FY2013 | Dec 31, 2013 | -$41.42M | – |
| FY2012 | Dec 31, 2012 | -$36.25M | – |
| FY2011 | Dec 31, 2011 | -$32.33M | – |
| FY2010 | Dec 31, 2010 | -$27.43M | – |
| FY2009 | Dec 31, 2009 | -$20.24M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $42.16M | +55.3% |
| Q1 FY2026 | Mar 31, 2026 | -$49.00M | -1363.6% |
| Q4 FY2025 | Dec 31, 2025 | $4.78M | -81.3% |
| Q3 FY2025 | Sep 30, 2025 | $10.15M | -78.4% |
| Q2 FY2025 | Jun 30, 2025 | $27.14M | -23.9% |
| Q1 FY2025 | Mar 31, 2025 | $3.88M | -86.9% |
| Q4 FY2024 | Dec 31, 2024 | $25.54M | -19.9% |
| Q3 FY2024 | Sep 30, 2024 | $46.92M | +49.4% |
| Q2 FY2024 | Jun 30, 2024 | $35.67M | +18.9% |
| Q1 FY2024 | Mar 31, 2024 | $29.62M | +97.1% |
| Q4 FY2023 | Dec 31, 2023 | $31.88M | +37.7% |
| Q3 FY2023 | Sep 30, 2023 | $31.41M | -2.2% |
| Q2 FY2023 | Jun 30, 2023 | $30.01M | -4.9% |
| Q1 FY2023 | Mar 31, 2023 | $15.03M | -44.5% |
| Q4 FY2022 | Dec 31, 2022 | $23.16M | -37.3% |
| Q3 FY2022 | Sep 30, 2022 | $32.13M | -7.0% |
| Q2 FY2022 | Jun 30, 2022 | $31.55M | -7.6% |
| Q1 FY2022 | Mar 31, 2022 | $27.06M | +36.0% |
| Q4 FY2021 | Dec 31, 2021 | $36.95M | +20.8% |
| Q3 FY2021 | Sep 30, 2021 | $34.54M | +39.3% |
| Q2 FY2021 | Jun 30, 2021 | $34.16M | -3.5% |
| Q1 FY2021 | Mar 31, 2021 | $19.89M | -47.6% |
| Q4 FY2020 | Dec 31, 2020 | $30.59M | -13.2% |
| Q3 FY2020 | Sep 30, 2020 | $24.80M | -25.3% |
| Q2 FY2020 | Jun 30, 2020 | $35.39M | +42.7% |
| Q1 FY2020 | Mar 31, 2020 | $37.95M | +99.2% |
| Q4 FY2019 | Dec 31, 2019 | $35.25M | +41.1% |
| Q3 FY2019 | Sep 30, 2019 | $33.22M | +44.2% |
| Q2 FY2019 | Jun 30, 2019 | $24.80M | +19.9% |
| Q1 FY2019 | Mar 31, 2019 | $19.05M | -9.5% |
| Q4 FY2018 | Dec 31, 2018 | $24.97M | +14.8% |
| Q3 FY2018 | Sep 30, 2018 | $23.03M | +68.6% |
| Q2 FY2018 | Jun 30, 2018 | $20.69M | +61.6% |
| Q1 FY2018 | Mar 31, 2018 | $21.04M | +342.7% |
| Q4 FY2017 | Dec 31, 2017 | $21.75M | +333.0% |
| Q3 FY2017 | Sep 30, 2017 | $13.66M | +341.6% |
| Q2 FY2017 | Jun 30, 2017 | $12.80M | – |
| Q1 FY2017 | Mar 31, 2017 | $4.75M | – |
| Q4 FY2016 | Dec 31, 2016 | $5.02M | – |
| Q3 FY2016 | Sep 30, 2016 | $3.09M | – |
See a number that looks wrong?